Prevention of Skin Carcinogenesis by the β-Blocker Carvedilol

The stress-related catecholamine hormones and the a-and beta-adrenergic receptors (alpha- and beta-AR) may affect carcinogenesis. The beta-AR GRK/beta-arrestin biased agonist carvedilol can induce beta-AR-mediated transactivation of the EGFR. The initial purpose of this study was to determine whether carvedilol, through activation of EGFR, can promote cancer. Carvedilol failed to promote anchorage-independent growth of JB6 P+ cells, a skin cell model used to study tumor promotion. However, at nontoxic concentrations, carvedilol dose dependently inhibited EGF-induced malignant transformation of JB6 P+ cells, suggesting that carvedilol has chemopreventive activity against skin cancer. Such effect was not observed for the C-AR agonist isoproterenol and the beta-AR antagonist atenolol. Gene expression, receptor binding, and functional studies indicate that JB6 P+ cells only express beta 2-ARs. Carvedilol, but not atenolol, inhibited EGF-mediated activator protein-1 (AP-1) activation. A topical 7,12-dimethylbenz(alpha)anthracene (DMBA)-induced skin hyperplasia model in SENCAR mice was utilized to determine the in vivo cancer preventative activity of carvedilol. Both topical and oral carvedilol treatment inhibited DMBA-induced epidermal hyperplasia (P < 0.05) and reduced H-ras mutations; topical treatment being the most potent. However, in models of established cancer, carvedilol had modest to no inhibitory effect on tumor growth of human lung cancer A549 cells in vitro and in vivo. In conclusion, these results suggest that the cardiovascular drug carvedilol may be repurposed for skin cancer chemoprevention, but may not be an effective treatment of established tumors. More broadly, this study suggests that beta-ARs may serve as a novel target for cancer prevention. (C) 2014 AACR.